Three F.D.A. Advisers Resign Over Approval of Alzheimer ' s Drug
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.
Source: NYT Health - Category: Consumer Health News Authors: Pam Belluck and Rebecca Robbins Tags: your-feed-science Alzheimer ' s Disease Drugs (Pharmaceuticals) Clinical Trials Aduhelm (Drug) Elderly Biogen Inc Source Type: news